~~<i id='DEA3FB8EC8'><strike id='DEA3FB8EC8'><tt id='DEA3FB8EC8'><pre id='DEA3FB8EC8'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：fashion 2025-10-02 05:46:30 Page View：58

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： H.R. 3 is the wrong path to lower drug costs
Next article： Virginia high school admissions case could be legal follow

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

A bus careens into a gulch in southern Mexico, leaving 27 people dead

MEXICOCITY--Apassengerbuslostcontrolandveeredoffaroadandintoa75-foot-deep(25meter-deep)gullyinsouthe

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

H.R. 3 is the wrong path to lower drug costs

Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.